# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095777
Filing Date
2024-08-13
Accepted
2024-08-13 08:19:02
Documents
82
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | mreo-20240630.htm iXBRL | 10-Q | 1938489
2 | EX-31.1 | mreo-ex31_1.htm | EX-31.1 | 21615
3 | EX-31.2 | mreo-ex31_2.htm | EX-31.2 | 21144
4 | EX-32.1 | mreo-ex32_1.htm | EX-32.1 | 7412
5 | EX-32.2 | mreo-ex32_2.htm | EX-32.2 | 7163
| Complete submission text file | 0000950170-24-095777.txt |  | 9205098

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | mreo-20240630.xsd | EX-101.SCH | 1538630
85 | EXTRACTED XBRL INSTANCE DOCUMENT | mreo-20240630_htm.xml | XML | 1616264

Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 241198888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)